siRNA药物降低慢性乙型肝炎患者血清HBsAg水平的研究进展
发布时间：2021-10-29 18:03
小干扰RNA（siRNA）主要参与RNA干扰,通过靶向HBV转录的mRNA并对其进行降解来阻止基因翻译。通过对siRNA进行化学修饰、结合使用和改进其传递体系,可增强siRNA的靶向性和稳定性。JNJ-3989（ARO-HBV）、ARB-1740作为耐受性良好、明显降低HBsAg水平的siRNA药物已进入临床研究。现主要阐述siRNA抑制HBsAg表达的机制、siRNA靶向性和稳定性的提高以及相关的临床前和临床研究。
【文章来源】：中华肝脏病杂志. 2020,28(02)
【文章页数】： 页
【参考文献】：
期刊论文
[1]人工外泌体共递送siRNA和蛋白的递送系统的设计及体外评价[J]. 邓赛,张灵敏,王萍,李仕颖,林潮金,傅小媚,余细勇. 药学学报. 2020(01)
[2]慢性乙型肝炎潜在治疗靶点和新药研发进展[J]. 郑金伟,袁权,夏宁邵. 微生物学报. 2019(08)
[3]siRNA药物研究进展[J]. 贺婉红,薛嫚,李芳,俸灵林,张婷. 中国药学杂志. 2018(14)
[4]不同物质修饰的阳离子脂质体的研究进展[J]. 冯莹莹,胡海梅. 中国药理学与毒理学杂志. 2018(06)
[5]小鼠模型中维生素E脂质体纳米颗粒靶向转运siRNA抑制丙型肝炎病毒核心蛋白表达[J]. 叶媛媛,陈红,颜艳,段亮,陈维贤,黄英. 中华肝脏病杂志. 2018 (05)
[6]Inhibition of HBV Replication by Delivering the Dual-gene Expression Vector pHsa-miR16-siRNA in HepG2.2.15 Cells[J]. 魏巍,汪速飞,余冰,倪明. Journal of Huazhong University of Science and Technology（Medical Sciences）. 2017(06)
[7]可递送siRNA的非病毒纳米载体的设计[J]. 赵晓乐,孔晓军,李剑勇. 国际药学研究杂志. 2016(04)
[8]非病毒siRNA载体研究进展[J]. 陈中华,朱德生,李军,黄展勤. 中国药理学通报. 2015(07)
[9]Combination of small interfering RNAs mediates greater suppression on hepatitis B virus cccDNA in HepG2.2.15 cells[J]. Xiao-Min Xin, Gui-Qiu Li,Ying-Yu Jin, Department of Laboratory Diagnosis, the First Affiliated Hospital of Harbin Medical University, Harbin 150081, Heilongjiang Province, China Min Zhuang, Di Li, Department of Microbiology, Harbin Medical University, Harbin 150081, Heilongjiang Province, China. World Journal of Gastroenterology. 2008(24)
[10]Combination of small interfering RNA and lamivudine on inhibition of human B virus replication in HepG2.2.15 cells[J]. Gui-Qiu Li, Wei-Zhen Xu, Jing-Xia Wang, Wen-Wei Deng, Di Li, Hong-Xi Gu Department of Microbiology, Harbin Medical University, Harbin 150081, Heilongjiang Province, China Department of Histology and Embryology, Jiamusi Medical College, Jiamusi University, Jiamusi 154002, Heilongjiang Province, China Department of Anesthesiology, Second Affiliated Hospital, Jiamusi University, Jiamusi 154002, Heilongjiang Province, China. World Journal of Gastroenterology. 2007(16)
本文编号：3465134
【文章来源】：中华肝脏病杂志. 2020,28(02)
【文章页数】： 页
【参考文献】：
期刊论文
[1]人工外泌体共递送siRNA和蛋白的递送系统的设计及体外评价[J]. 邓赛,张灵敏,王萍,李仕颖,林潮金,傅小媚,余细勇. 药学学报. 2020(01)
[2]慢性乙型肝炎潜在治疗靶点和新药研发进展[J]. 郑金伟,袁权,夏宁邵. 微生物学报. 2019(08)
[3]siRNA药物研究进展[J]. 贺婉红,薛嫚,李芳,俸灵林,张婷. 中国药学杂志. 2018(14)
[4]不同物质修饰的阳离子脂质体的研究进展[J]. 冯莹莹,胡海梅. 中国药理学与毒理学杂志. 2018(06)
[5]小鼠模型中维生素E脂质体纳米颗粒靶向转运siRNA抑制丙型肝炎病毒核心蛋白表达[J]. 叶媛媛,陈红,颜艳,段亮,陈维贤,黄英. 中华肝脏病杂志. 2018 (05)
[6]Inhibition of HBV Replication by Delivering the Dual-gene Expression Vector pHsa-miR16-siRNA in HepG2.2.15 Cells[J]. 魏巍,汪速飞,余冰,倪明. Journal of Huazhong University of Science and Technology（Medical Sciences）. 2017(06)
[7]可递送siRNA的非病毒纳米载体的设计[J]. 赵晓乐,孔晓军,李剑勇. 国际药学研究杂志. 2016(04)
[8]非病毒siRNA载体研究进展[J]. 陈中华,朱德生,李军,黄展勤. 中国药理学通报. 2015(07)
[9]Combination of small interfering RNAs mediates greater suppression on hepatitis B virus cccDNA in HepG2.2.15 cells[J]. Xiao-Min Xin, Gui-Qiu Li,Ying-Yu Jin, Department of Laboratory Diagnosis, the First Affiliated Hospital of Harbin Medical University, Harbin 150081, Heilongjiang Province, China Min Zhuang, Di Li, Department of Microbiology, Harbin Medical University, Harbin 150081, Heilongjiang Province, China. World Journal of Gastroenterology. 2008(24)
[10]Combination of small interfering RNA and lamivudine on inhibition of human B virus replication in HepG2.2.15 cells[J]. Gui-Qiu Li, Wei-Zhen Xu, Jing-Xia Wang, Wen-Wei Deng, Di Li, Hong-Xi Gu Department of Microbiology, Harbin Medical University, Harbin 150081, Heilongjiang Province, China Department of Histology and Embryology, Jiamusi Medical College, Jiamusi University, Jiamusi 154002, Heilongjiang Province, China Department of Anesthesiology, Second Affiliated Hospital, Jiamusi University, Jiamusi 154002, Heilongjiang Province, China. World Journal of Gastroenterology. 2007(16)
本文编号：3465134
本文链接：https://www.wllwen.com/projectlw/zzkxlw/3465134.html
